title: Creating a "Prosurvival Phenotype" Through Histone Deacetylase Inhibition: Past, Present, and Future.
abstract: Traumatic injuries and their sequelae represent a major source of mortality in the United States and globally. Initial treatment for shock, traumatic brain injury, and polytrauma is limited to resuscitation fluids to replace lost volume. To date, there are no treatments with inherent prosurvival properties. Our laboratory has investigated the use of histone deacetylase inhibitors (HDACIs) as pharmacological agents to improve survival. This class of drugs acts through posttranslational protein modifications and is a direct regulator of chromatin structure and function, as well as the function of numerous cytoplasmic proteins. In models of hemorrhagic shock and polytrauma, administration of HDACIs offers a significant survival advantage, even in the absence of fluid resuscitation. Positive results have also been shown in two-hit models of hemorrhage and sepsis and in hemorrhagic shock combined with traumatic brain injury. Accumulating data generated by our group and others continue to support the use of HDACIs for the creation of a prosurvival phenotype. With further research and clinical trials, HDACIs have the potential to be an integral tool in the treatment of trauma, especially in the prehospital phase.
authors.affiliation: Department of Surgery, University of Michigan, Ann Arbor, Michigan.
authors.forename: Ihab
authors.initials: I
authors.lastname: Halaweish
authors.forename: Vahagn
authors.initials: V
authors.lastname: Nikolian
authors.forename: Patrick
authors.initials: P
authors.lastname: Georgoff
authors.forename: Yongqing
authors.initials: Y
authors.lastname: Li
authors.forename: Hasan B
authors.initials: HB
authors.lastname: Alam
mesh_terms: D000818:Animals; D001930:Brain Injuries / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D003593:Cytoplasm / Q000378:metabolism; D044127:Epigenesis, Genetic; D006470:Hemorrhage / Q000473:pathology / Q000628:therapy*; D056572:Histone Deacetylase Inhibitors / Q000737:chemistry*; D006655:Histone Deacetylases / Q000378:metabolism; D006801:Humans; D010641:Phenotype; D011499:Protein Processing, Post-Translational; D018805:Sepsis / Q000503:physiopathology; D012771:Shock, Hemorrhagic / Q000378:metabolism / Q000628:therapy; D013552:Swine; D014947:Wounds and Injuries
chemical_list: D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases